Please provide your email address to receive an email when new articles are posted on . Men with low- or intermediate-risk prostate cancer achieved similar quality-of-life outcomes whether they ...

People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy - proton beam therapy or intensity modulated radiation therapy (IMRT) - ...

SAN FRANCISCO, September 29, 2025 — A new phase III clinical trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low ...

A new phase III clinical trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people ...

The first randomized trial to compare proton therapy with conventional radiotherapy has not found a difference in toxicity, which is the main claim for superiority of proton therapy. The trial was ...

Patient-reported quality of life (QoL) was similar between proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT) among men with localized prostate cancer, the randomized PARTIQoL ...

Proton Therapy reduces the risk of a second cancer diagnosis by 69% versus other forms of radiation treatment according to a paper recently released by a team from Stanford University. The study ...

Please provide your email address to receive an email when new articles are posted on . Risk for late feeding tube dependence was low and did not differ between intensity-modulated radiation therapy ...

Radiation therapy is a treatment that uses high-energy rays, like X-rays, gamma rays or protons, to target and destroy cancer cells. It works by damaging the DNA of cancer cells, preventing them from ...

A study by investigators from Mass General Brigham Cancer Institute evaluates the efficacy and safety of proton therapy for patients with lower grade gliomas (LGGs). The single-arm prospective phase 2 ...

Proton beam therapy does not improve the patient-reported outcome of bowel function compared with IMRT. Bowel side effects do not differ between patients with localized prostate cancer who receive ...